Fortitude Family Office’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$90.5K Buy
1,451
+246
+20% +$15.5K 0.02% 285
2026
Q2
$69.4K Buy
1,205
+542
+82% +$31.1K 0.01% 226
2026
Q1
$40.2K Sell
663
-4,883
-88% -$285K 0.01% 271
2025
Q4
$299K Buy
5,546
+56
+1% +$2.69K 0.07% 117
2025
Q3
$248K Sell
5,490
-32
-0.6% -$1.49K 0.07% 126
2025
Q2
$256K Sell
5,522
-1,149
-17% -$56.4K 0.08% 111
2025
Q1
$407K Sell
6,671
-2,869
-30% -$167K 0.14% 76
2024
Q4
$540K Sell
9,540
-43
-0.4% -$2.4K 0.19% 71
2024
Q3
$496K Buy
9,583
+3,033
+46% +$142K 0.2% 64
2024
Q2
$272K Hold
6,550
– – 0.15% 73
2024
Q1
$355K Sell
6,550
-31
-0.5% -$1.58K 0.24% 57
2023
Q4
$338K Buy
+6,581
New +$345K 0.25% 62

Other funds holding BMY

Fortitude Family Office's BMY Position: Q3 2026 in Review

Fortitude Family Office increased its Bristol-Myers Squibb (BMY) stake by 20% in Q3 2026, buying an estimated $15.5K and bringing the position to 1,451 shares worth $90.5K. The position accounts for 0.02% of the portfolio, ranked #285.

Fortitude Family Office first reported a position in BMY in Q4 2023 and has held it in 12 quarters since. The position peaked at $540K in Q4 2024. 340 funds tracked by Wall St. Rank hold BMY as of Q3 2026.

  • Fortitude Family Office held 1,451 shares of Bristol-Myers Squibb worth $90.5K as of Q3 2026.
  • Fortitude Family Office bought 246 Bristol-Myers Squibb shares in Q3 2026, an estimated $15.5K.
  • Bristol-Myers Squibb made up 0.02% of Fortitude Family Office's portfolio in Q3 2026, its #285 holding.
  • Fortitude Family Office first reported a position in Bristol-Myers Squibb in Q4 2023 and has held it in 12 quarters since.
  • Fortitude Family Office's Bristol-Myers Squibb position peaked at $540K in Q4 2024.
  • 340 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2026.

Based on Fortitude Family Office's 13F filing for Q3 2026, filed 14 Oct 2026.